Vertex to Acquire Crinetics
Vertex to Acquire Crinetics in a definitive all-cash merger at $85 per share, valuing it near $10.0 billion and refocusing traders on the closing timeline.
KEY TAKEAWAYS
- Vertex agreed to acquire Crinetics for $85 per share, valuing it at about $10.0 billion.
- The all-cash merger has an expected close in Q3 2026, subject to shareholder and regulatory approvals.
- The deal adds PALSONIFY and Phase-3 atumelnant with roughly $5.0 billion in peak annual sales potential.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will acquire Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), the companies said in a joint press release on July 6, 2026. The all-cash merger adds a commercial acromegaly drug and a Phase 3 endocrinology asset to Vertex’s pipeline.
Deal Terms and Timeline
Under a definitive merger agreement, Vertex will acquire all outstanding shares of Crinetics for $85.00 per share, valuing the company’s equity at approximately $10.0 billion, the companies said in a joint Business Wire release at 16:04 ET. The transaction is expected to close in the third quarter of 2026, subject to approval by Crinetics shareholders and customary regulatory clearances. Crinetics shares more than doubled in after-hours trading following the announcement.
Pipeline and Revenue Potential
The acquisition adds PALSONIFY, Crinetics’ commercial treatment for acromegaly, and atumelnant, a Phase 3 endocrinology asset, to Vertex’s portfolio. The companies said the combined endocrinology assets have roughly $5 billion in peak annual sales potential. Vertex described the deal as expanding its presence in endocrinology and rare endocrine diseases, broadening its pipeline beyond existing therapeutic areas.
The companies framed the peak-sales figure as an estimate of market potential rather than formal revenue guidance. The announcement did not include detailed pro forma or earnings accretion forecasts, leaving the financial impact dependent on commercial uptake of PALSONIFY and clinical progress of the Phase 3 program.
With the cash price and timetable set, the transaction establishes a clear near-term valuation baseline. Market focus will shift to execution of the closing timeline and the commercial prospects of the acquired assets.
